Genmab
Transforming Antibody Therapeutics
About Genmab
Funding & Growth
✓ Pros
- • Leader in antibody therapeutics (Darzalex, bispecifics)
- • Strong science-driven culture
- • Global opportunities (Denmark, US, Japan)
- • Growing computational biology focus
- • Collaborative team environment
✗ Cons
- • Smaller than big pharma (fewer roles)
- • Denmark HQ means some decisions made overseas
- • Less brand recognition in US vs European markets
🏢 Working Here
Genmab operates with an 'extra[not]ordinary' culture emphasizing authenticity and innovation.
The company has pioneered next-generation antibody technologies including bispecific T-cell engagers, antibody-drug conjugates, and effector function enhanced antibodies.
Scientists work in multidisciplinary, international teams with state-of-the-art knowledge of the antibody and oncology field.
The US headquarters in Princeton, NJ focuses on clinical development and commercial operations, while Copenhagen remains the R&D hub.
Genmab supports employee resource groups including GenPride, GenWEN, and NextGen for early career professionals.
🧬 Bioinformatics Focus
Genmab is transforming antibody discovery using computational biology and bioinformatics. Key areas include:
- Discovery Data Science - Integrating ML/AI into early drug discovery for antibody optimization.
- Translational Sciences - Using quantitative approaches to bridge preclinical and clinical development.
- Computational Immunology - Analyzing immune responses and tumor microenvironment.
- Single - cell and spatial transcriptomics for understanding antibody mechanisms. The team combines wet lab and computational approaches to optimize bispecific antibodies and ADCs.
📈 Career Growth & Development
Development
Genmab follows a 70-20-10 learning model for professional development.
Career Tracks
Scientists can progress through individual contributor tracks (Scientist I → Senior → Principal → Distinguished) or move into leadership roles.
Growth
The company's growth in bispecific antibodies and ADCs creates opportunities in computational biology and translational sciences.
Mobility
Global mobility between Copenhagen, Princeton, Utrecht, and Tokyo offices is possible.